The Cancer Business – A Fight For Control

The cancer industry (pharmaceutical firms, ACS, FDA, NCI, AMA) presents a strong appearance of service and progress. Behind the scenes though, their top priority is the corporate bottom line. After all, medicine is a business. As in any business relationship the caveat “buyer beware” should apply. However buyers are not aware. Most have been lulled into a strong delusion by effective medical marketing–marketing that is silent on the vast array of working alternative treatments. This is understandable, as alternatives represent competition. They are bad for business, generally requiring minimal or no visits to a doctor, and no prescription medications.